Synapse

← Brett P. Monia

Papers by Brett P. Monia

Page 1 · newest first

  1. Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermediaBlood Advances · 2026
  2. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with SefaxersenImmunobiology · 2025
  3. Prothrombin prevents fatal T cell-dependent anemia during chronic virus infection of mice2024
  4. TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisAdvances in Therapy · 2023
  5. Targeting the contact system in a rabbit model of extracorporeal membrane oxygenationBlood Advances · 2022
  6. Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosisBritish Journal of Clinical Pharmacology · 2022
  7. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathwayNature Communications · 2022
  8. In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin ProteolysisInternational Journal of Molecular Sciences · 2021
  9. An oral antisense oligonucleotide for PCSK9 inhibitionScience Translational Medicine · 2021
  10. Antisense oligonucleotide‐mediated knockdown ofMpzl3attenuates the negative metabolic effects of diet‐induced obesity in miceSHILAP Revista de lepidopterología · 2021
  11. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid PolyneuropathyNeurology and Therapy · 2021
  12. Ligand Conjugated Antisense Oligonucleotide for the Treatment of Transthyretin Amyloidosis: Preclinical and Phase 1 DataESC Heart Failure · 2020
  13. Immunogenicity Assessment of Inotersen, a 2′- O -(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and SafetyNucleic Acid Therapeutics · 2020
  14. SERPINA1 modulates expression of amyloidogenic transthyretinExperimental Cell Research · 2020
  15. Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin AmyloidosisNucleic Acid Therapeutics · 2020
  16. Antisense Oligonucleotides Targeting Jagged 1 Reduce House Dust Mite–induced Goblet Cell Metaplasia in the Adult Murine LungAmerican Journal of Respiratory Cell and Molecular Biology · 2020
  17. Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated ThrombocytopeniaNucleic Acid Therapeutics · 2020
  18. Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT miceBlood Advances · 2019
  19. Steric Inhibition of 5′ UTR Regulatory Elements Results in Upregulation of Human CFTRMolecular Therapy · 2019
  20. Antisense oligonucleotide treatment ameliorates IFN-γ–induced proteinuria in APOL1-transgenic miceJCI Insight · 2019
  21. Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense MutationsNucleic Acid Therapeutics · 2019
  22. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune EvasionCancer Research · 2019
  23. Sex-specific differences in emphysema using a murine antisense oligonucleotide model of α-1 antitrypsin deficiencyAJP Lung Cellular and Molecular Physiology · 2019
  24. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTRAmerican Journal of Respiratory Cell and Molecular Biology · 2019
  25. IONIS-PKK Rx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin ProductionNucleic Acid Therapeutics · 2019
  26. Inotersen ( Transthyretin -Specific Antisense Oligonucleotide) for Treatment of Transthyretin AmyloidosisNeurodegenerative Disease Management · 2018
  27. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialJournal for ImmunoTherapy of Cancer · 2018
  28. Reducing dynamin 2 (DNM2) rescues DNM2 -related dominant centronuclear myopathyProceedings of the National Academy of Sciences · 2018
  29. Targeted delivery of antisense oligonucleotides to pancreatic β-cellsScience Advances · 2018
  30. Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisNew England Journal of Medicine · 2018
  31. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialAmyloid · 2018
  32. Role for Cela1 in Postnatal Lung Remodeling and Alpha-1 Antitrypsin–Deficient EmphysemaAmerican Journal of Respiratory Cell and Molecular Biology · 2018
  33. Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutationsGenome biology · 2018
  34. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRASScience Translational Medicine · 2017
  35. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in miceNature Communications · 2017
  36. Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx)Amyloid · 2017
  37. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertensionScience Translational Medicine · 2017
  38. Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like CellsPLoS ONE · 2016
  39. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesAmyloid · 2016
  40. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerScience Translational Medicine · 2015
  41. Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell DegenerationInvestigative Ophthalmology & Visual Science · 2015
  42. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermediaHaematologica · 2015
  43. Reversing Antisense Oligonucleotide Activity with a Sense Oligonucleotide Antidote: Proof of Concept Targeting ProthrombinNucleic Acid Therapeutics · 2015
  44. Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease miceBlood · 2015
  45. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in miceImmunobiology · 2015
  46. Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and FibrinogenCancer Research · 2015
  47. Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoproteinBlood · 2015
  48. Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell GrowthClinical Cancer Research · 2015
  49. Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese MiceDiabetes · 2014
  50. Factor XI Antisense Oligonucleotide for Prevention of Venous ThrombosisNew England Journal of Medicine · 2014